Boehringer Ingelheim· @Boehringer · X·· 2026-07-16AI 评分40
AI 导读
#NEWS：我们用于 #obesity 的在研三重受体激动剂已启动II期试验。 该试验将有助于推动对肥胖的生物学和行为学驱动因素的理解，以改善健康结局。 阅读更多 👉 https://go.boehringer.com/dQ-Zj #LifeForward
正文
#NEWS: Phase II trial initiated for our investigational triple receptor agonist for #obesity.
This trial will help drive understanding of both biological and behavioural drivers of obesity to improve health outcomes.
Read more 👉 https://go.boehringer.com/dQ-Zj
#LifeForward
来源：Boehringer Ingelheim · x.com